Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Osimertinib Mesylate

FDA-approved product (tablet, oral), marketed as Tagrisso.

Registered studies
26
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Osimertinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

26registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Osimertinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Osimertinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.

    NCT07603791 · start 2026-06-30

    Registered record
    Registry ID
    NCT07603791
    Conditions
    NSCLC (Advanced Non-small Cell Lung Cancer)
    Interventions
    ALK202 for injection; Osimertinib Mesylate Tablets; Ivonescimab Injection; carboplatin injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06-30
    Completion
    2028-12-30
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Advanced Non-small Cell Lung Cancer)
    InterventionALK202 for injection; Osimertinib Mesylate Tablets; Ivonescimab Injection; carboplatin injection
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

    NCT07256509 · start 2025-11-30

    Registered record
    Registry ID
    NCT07256509
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    SYS6010; Osimertinib; Pemetrexed; Cisplatin; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-11-30
    Completion
    2032-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionSYS6010; Osimertinib; Pemetrexed; Cisplatin +1 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

    NCT07229729 · start 2025-11-24

    Registered record
    Registry ID
    NCT07229729
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    SHR-A2102; Adebrelimab; Paclitaxel; Carboplatin; Alomnertinib Mesilate; Furmonertini Mesilate; Osimertinib Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-24
    Completion
    2029-10
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionSHR-A2102; Adebrelimab; Paclitaxel; Carboplatin +3 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

    NCT06829459 · start 2025-04-03

    Registered record
    Registry ID
    NCT06829459
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Glumetinib; Osimertinib mesylate; Pemetrexed; Cisplatin or carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-03
    Completion
    2029-02-15
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionGlumetinib; Osimertinib mesylate; Pemetrexed; Cisplatin or carboplatin
    PhasePhase 3
    Registry statusRecruiting

  • Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

    NCT06908772 · start 2025-04-01

    Registered record
    Registry ID
    NCT06908772
    Conditions
    Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
    Interventions
    Glumetinib Tablets; Osimertinib Mesylate Tablets; Glumetinib Tablets Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-04-01
    Completion
    2030-01-31
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
    InterventionGlumetinib Tablets; Osimertinib Mesylate Tablets; Glumetinib Tablets Placebo
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

    NCT06895928 · start 2025-03-28

    Registered record
    Registry ID
    NCT06895928
    Conditions
    Advanced Solid Tumors
    Interventions
    SHR-A2102; Bevacizumab Injection; Adebelimab Injection; Ametinib Mesylate Tablets; Osimertinib Mesylate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-28
    Completion
    2028-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionSHR-A2102; Bevacizumab Injection; Adebelimab Injection; Ametinib Mesylate Tablets +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

    NCT06692491 · start 2025-01-01

    Registered record
    Registry ID
    NCT06692491
    Conditions
    Rare Tumour
    Interventions
    Albumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine; Cisplatin; Irinotecan; Fluorouracil; Nivolumab; Pembrolizumab; Durvalumab; Atezolizumab; Sintilimab; Tislelizumab; Camrelizumab; Toripalimab; Serplulimab; Adebrelimab; Envafolimab; Osimertinib; Alectinib; Vemurafenib; Pamiparib; Pyrotinib; Imatinib; Palbociclib; Savolitinib; Entrectinib; Other
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2029-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRare Tumour
    InterventionAlbumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine +24 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

    NCT07322783 · start 2025-01-01

    Registered record
    Registry ID
    NCT07322783
    Conditions
    EGFR Positive Non-small Cell Lung Cancer; MET Amplification
    Interventions
    • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-01-01
    Completion
    2026-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEGFR Positive Non-small Cell Lung Cancer; MET Amplification
    Intervention• Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets
    PhasePhase 2
    Registry statusRecruiting

  • A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

    NCT06970639 · start 2024-09-26

    Registered record
    Registry ID
    NCT06970639
    Conditions
    NSCLC Patients With Brain Metastasis
    Interventions
    Furmonertinib Mesilate Tablets; Carboplatin Injection; Cisplatin for injection; Pemetrexed Disodium for Injection; Osimertinib Mesylate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-09-26
    Completion
    2029-09
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC Patients With Brain Metastasis
    InterventionFurmonertinib Mesilate Tablets; Carboplatin Injection; Cisplatin for injection; Pemetrexed Disodium for Injection +1 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

    NCT06498986 · start 2024-07-31

    Registered record
    Registry ID
    NCT06498986
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    BL-B01D1; Osimertinib Mesylate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-07-31
    Completion
    2026-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionBL-B01D1; Osimertinib Mesylate Tablets
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

    NCT06530719 · start 2024-07

    Registered record
    Registry ID
    NCT06530719
    Conditions
    Lung Neoplasms; Lung Cancer, Nonsmall Cell
    Interventions
    Osimertinib mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-07
    Completion
    2028-05
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Neoplasms; Lung Cancer, Nonsmall Cell
    InterventionOsimertinib mesylate
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

    NCT06306456 · start 2024-03-05

    Registered record
    Registry ID
    NCT06306456
    Conditions
    Non-Small Cell Lung Cancer With EGFR Mutation
    Interventions
    GH21; Tagrisso
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-03-05
    Completion
    2026-12-31
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer With EGFR Mutation
    InterventionGH21; Tagrisso
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

    NCT05880706 · start 2023-07-19

    Registered record
    Registry ID
    NCT05880706
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    BL-B01D1; Osimertinib Mesylate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-07-19
    Completion
    2027-07
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionBL-B01D1; Osimertinib Mesylate Tablets
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

    NCT05816252 · start 2023-04-19

    Registered record
    Registry ID
    NCT05816252
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    SKB264; Pembrolizumab; Carboplatin; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-04-19
    Completion
    2026-12-30
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionSKB264; Pembrolizumab; Carboplatin; Osimertinib
    PhasePhase 2
    Registry statusActive not recruiting

  • VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

    NCT05489731 · start 2022-09-21

    Registered record
    Registry ID
    NCT05489731
    Conditions
    Advanced Non-small Cell Lung Cancer
    Interventions
    VIC-1911; Osimertinib Mesylate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-09-21
    Completion
    2024-04-24
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-small Cell Lung Cancer
    InterventionVIC-1911; Osimertinib Mesylate Tablets
    PhasePhase 1
    Registry statusUnknown